YC-1
CHF 30.00
In stock
AG-CR1-0120-M0011 mgCHF 30.00
AG-CR1-0120-M0055 mgCHF 90.00
AG-CR1-0120-M02525 mgCHF 360.00
| Product Details | |
|---|---|
| Synonyms | 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole |
| Product Type | Chemical |
| Properties | |
| Formula | C19H16N2O2 |
| MW | 304.4 |
| CAS | 170632-47-0 |
| Purity Chemicals | ≥98% (NMR) |
| Appearance | White to pale yellow powder. |
| Solubility | Soluble in DMSO, methanol or dichloromethane. |
| Identity | Determined by 1H-NMR. |
| InChi Key | OQQVFCKUDYMWGV-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Nitric oxide (NO) independent, superoxide-sensitive soluble guanylyl cyclase (sGC) activator [1, 4].
- Induces concentration-dependent increase in cGMP levels [1, 4].
- Inhibits platelet adhesion to collagen [2, 8].
- Thombosis inhibitor [3].
- Non-specific phosphodiesterase inhibitor [5].
- Na+ channel blocker [6, 9].
- Anticancer compound [7, 8].
- HIF-α inhibitor [7, 10].
- Blocks angiogenesis. Tumor growth inhibitor [7, 10].
- Apoptosis inducer [11].
- NK cell differentiation enhancer [12].
- TRAIL sensitizer [13].
Product References
- YC-1, a novel activator of platelet guanylate cyclase: F.N. Ko, et al.; Blood 84, 4226 (1994)
- YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase: C.C. Wu, et al.; Br. J. Pharmacol. 116, 1973 (1995)
- YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice: C.M. Teng, et al.; Eur. J. Pharmacol. 320, 161 (1997)
- Mechanism of YC-1-induced activation of soluble guanylyl cyclase: A. Friebe & D. Koesling; Mol. Pharmacol. 53, 123 (1998)
- BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase: M. Koglin, et al.; BBRC 292, 1057 (2002)
- Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition: G. Garthwaite, et al.; Mol. Pharmacol. 61, 97 (2002)
- YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1: E.J. Yeo, et al.; J. Natl. Cancer Inst. 95, 516 (2003)
- Versatile pharmacological actions of YC-1: anti-platelet to anticancer: Y.S. Chun, et al.; Cancer Lett. 207, 1 (2004) (Review)
- A Novel Drug Binding Site on Voltage-Gated Sodium Channels in Rat Brain: D. R. Riddall, et al.; Mol. Pharmacol. 69, 278 (2006)
- Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading: D.H. Shin, et al.; Cancer Lett. 255, 107 (2007)
- YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway: S.Y. Wu, et al.; Br. J. Pharmacol. 155, 505 (2008)
- YC-1 enhances natural killer cell differentiation from hematopoietic stem cells: S. Yun, et al.; Int. Immunopharmacol. 10, 481 (2010)
- Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis: D. Finlay, et al.; PLoS One 5, e13375 (2010)
Related Products
